According to the latest financial report of X4 PHARMACEUTICALS INC C/WTS 16/04/24(TO PUR COM) CL A, the latest earnings per share (TTM) for the company is --. Investing in companies with strong earnings per share can potentially provide higher returns.
Interested in knowing about X4 PHARMACEUTICALS INC C/WTS 16/04/24(TO PUR COM) CL A's free cash flow? The latest report shows it as -27.78M. Keep an eye on and closely monitor the company's cash flow to make informed investment decisions.
If you are evaluating a company's liquidity, current ratio is an important measure to consider. The latest financial report of X4 PHARMACEUTICALS INC C/WTS 16/04/24(TO PUR COM) CL A shows that the company's current ratio is 5.34, indicating healthy liquidity.
Another liquidity indicator to closely monitor is quick ratio. According to the latest financial results of X4 PHARMACEUTICALS INC C/WTS 16/04/24(TO PUR COM) CL A, the quick ratio is 5.02, indicating that the company can meet its short-term debt obligations.
Want to learn more about the financial health of X4 PHARMACEUTICALS INC C/WTS 16/04/24(TO PUR COM) CL A? The latest ROE figure is -32.23%, indicating that the company has stable profitability.
Investors looking for profitability indicators may be interested in ROA. According to the latest financial results of X4 PHARMACEUTICALS INC C/WTS 16/04/24(TO PUR COM) CL A, the total asset return on investment (ROA) is -11.94%.
Gross margin can provide insight into a company's pricing strategy and cost structure. Check X4 PHARMACEUTICALS INC C/WTS 16/04/24(TO PUR COM) CL A's latest financial report to see how their gross margin is doing - currently at --.
For investors focusing on operational efficiency, net profit margin is an important indicator. According to the latest financial results of X4 PHARMACEUTICALS INC C/WTS 16/04/24(TO PUR COM) CL A, the net profit margin is -371.27%, which is a good sign for its profitability.